Cargando…

The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis

Background: Neoadjuvant systemic therapy (NST) is commonly used in patients with early stage breast cancer before definitive surgery. The standard diagnostic approach for pathologic complete response (pCR) of the breast is breast surgery and pathologic examination. In recent years, several trials in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhou, Yidong, Mao, Feng, Lin, Yan, Zhang, Xiaohui, Shen, Songjie, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333530/
https://www.ncbi.nlm.nih.gov/pubmed/32676452
http://dx.doi.org/10.3389/fonc.2020.00933
_version_ 1783553772459393024
author Li, Yan
Zhou, Yidong
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
author_facet Li, Yan
Zhou, Yidong
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
author_sort Li, Yan
collection PubMed
description Background: Neoadjuvant systemic therapy (NST) is commonly used in patients with early stage breast cancer before definitive surgery. The standard diagnostic approach for pathologic complete response (pCR) of the breast is breast surgery and pathologic examination. In recent years, several trials investigated the predictive value of image-guided minimally invasive biopsy (MIB) for breast pCR after NST. This study conducted a meta-analysis to evaluate the diagnostic accuracy of MIB. Materials and Methods: We identified relevant research reports in online databases through February 2020. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate the quality of included trials. We extracted relevant data and constructed a 2 × 2 contingency table to analyze the predictive accuracy of MIB for breast pCR. Subgroup analyses and meta-regressions were also performed to investigate potential causes of heterogeneity. Results: Nine trials (with 1,030 breast cancer patients) were included in this meta-analysis. The pooled sensitivity and specificity of MIB were 0.72 [95% confidence interval (CI): 0.61–0.81] and 0.99 (95% CI: 0.89–1.00), respectively. By combining relevant data, there were no significant differences in sensitivity or specificity among different molecular subtypes of breast cancer (P > 0.05). Subgroup analyses and meta-regressions implied that trials with responses not limited to clinical complete response (cCR) had a significantly higher accuracy of MIB than those with only cCR (RDOR: 7.65; 95% CI: 1.05–55.46; P = 0.046). Conclusion: Current image-guided MIB methods are not accurate enough in terms of predicting breast pCR after NST. It is of utmost clinical importance to standardize the MIB procedure and incorporate other factors into the evaluation in order to improve the accuracy to an acceptable level.
format Online
Article
Text
id pubmed-7333530
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73335302020-07-15 The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis Li, Yan Zhou, Yidong Mao, Feng Lin, Yan Zhang, Xiaohui Shen, Songjie Sun, Qiang Front Oncol Oncology Background: Neoadjuvant systemic therapy (NST) is commonly used in patients with early stage breast cancer before definitive surgery. The standard diagnostic approach for pathologic complete response (pCR) of the breast is breast surgery and pathologic examination. In recent years, several trials investigated the predictive value of image-guided minimally invasive biopsy (MIB) for breast pCR after NST. This study conducted a meta-analysis to evaluate the diagnostic accuracy of MIB. Materials and Methods: We identified relevant research reports in online databases through February 2020. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate the quality of included trials. We extracted relevant data and constructed a 2 × 2 contingency table to analyze the predictive accuracy of MIB for breast pCR. Subgroup analyses and meta-regressions were also performed to investigate potential causes of heterogeneity. Results: Nine trials (with 1,030 breast cancer patients) were included in this meta-analysis. The pooled sensitivity and specificity of MIB were 0.72 [95% confidence interval (CI): 0.61–0.81] and 0.99 (95% CI: 0.89–1.00), respectively. By combining relevant data, there were no significant differences in sensitivity or specificity among different molecular subtypes of breast cancer (P > 0.05). Subgroup analyses and meta-regressions implied that trials with responses not limited to clinical complete response (cCR) had a significantly higher accuracy of MIB than those with only cCR (RDOR: 7.65; 95% CI: 1.05–55.46; P = 0.046). Conclusion: Current image-guided MIB methods are not accurate enough in terms of predicting breast pCR after NST. It is of utmost clinical importance to standardize the MIB procedure and incorporate other factors into the evaluation in order to improve the accuracy to an acceptable level. Frontiers Media S.A. 2020-06-26 /pmc/articles/PMC7333530/ /pubmed/32676452 http://dx.doi.org/10.3389/fonc.2020.00933 Text en Copyright © 2020 Li, Zhou, Mao, Lin, Zhang, Shen and Sun. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yan
Zhou, Yidong
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title_full The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title_fullStr The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title_full_unstemmed The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title_short The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis
title_sort diagnostic performance of minimally invasive biopsy in predicting breast pathological complete response after neoadjuvant systemic therapy in breast cancer: a meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333530/
https://www.ncbi.nlm.nih.gov/pubmed/32676452
http://dx.doi.org/10.3389/fonc.2020.00933
work_keys_str_mv AT liyan thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT zhouyidong thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT maofeng thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT linyan thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT zhangxiaohui thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT shensongjie thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT sunqiang thediagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT liyan diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT zhouyidong diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT maofeng diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT linyan diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT zhangxiaohui diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT shensongjie diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis
AT sunqiang diagnosticperformanceofminimallyinvasivebiopsyinpredictingbreastpathologicalcompleteresponseafterneoadjuvantsystemictherapyinbreastcancerametaanalysis